Novo Nordisk presented new data from the retrospective, observational SCORE study that assessed treatment with Wegovy® (semaglutide injection) 2.4 mg and the risk of major adverse cardiovascular events (MACE) in adults living with overweight or obesity and established cardiovascular disease (CVD).

Novo Nordisk today presented full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (semaglutide tablets, 14mg) significantly reduced the risk of major adverse cardiovascular events in adults living with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD).

Novo Nordisk has secured global rights to China-based United Laboratories International's experimental weight-loss drug, UBT251, in a deal worth up to $2 billion.

A new study has found that planned non-labour caesarean section (NLCS) is associated with a reduced risk of complications in pregnant women living with obesity compared to spontaneous labour.

A new study has found that extreme weight fluctuations — both gain and loss — significantly increase the risk of death in individuals living with obesity and cardiovascular disease.

A new study has highlighted a concerning connection between obesity, high stress levels, and pancreatic cancer — one of the deadliest forms of the disease.

Zealand Pharma has officially partnered with Roche to develop and commercialise its lead obesity treatment candidate, petrelintide, marking a major milestone in the company’s obesity drug pipeline.

New research from the University of Cambridge has identified a genetic link between obesity in humans and Labrador Retrievers, shedding light on the fundamental biology of weight gain.

Novo Nordisk has announced promising results from the REDEFINE 2 trial, a pivotal phase 3 study investigating the efficacy and safety of CagriSema in people living with obesity or overweight and type 2 diabetes.

A new study has found that GLP-1 receptor agonists, may significantly benefit kidney transplant recipients with type 2 diabetes. The research, published in The Lancet Diabetes and Endocrinology, suggests that these medications reduce the risk of organ failure and improve survival rates in transplant patients.

A new report published in The Lancet Diabetes and Endocrinology is set to reshape how obesity is diagnosed, moving beyond the traditional Body Mass Index (BMI) measurement to a more comprehensive definition based on adiposity and its impact on the body.

A new global study published in The Lancet has revealed that over half of all adults and a third of children, teenagers, and young adults worldwide are expected to be overweight or obese by 2050. The research, which analyses data from more than 200 countries, highlights the rapid acceleration of obesity levels, particularly in lower-income nations.

A new study published in JAMA Network Open suggests that closely following a Mediterranean diet may help lower the risk of obesity-related cancers, regardless of body weight.

A recent study has identified Leeds as the unhealthiest city in the UK, based on a range of lifestyle and health indicators.

New research has revealed that just 24 hours without sleep can cause a spike in immune cells associated with chronic inflammation, a key driver of obesity.

A new study from The University of Texas at Arlington (UTA) has revealed that adolescents who perceive themselves as overweight are three times more likely to consider self-harm, regardless of their actual weight.